361 Studies Now Enrolling
C3300201: A Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome
Study of IW-3300 in Patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
| Sponsor: | Ironwood Pharmaceuticals, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU6981 |
| U.S. Govt. ID: | NCT05740007 |
| Contact: | Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to find out if IW-3300, an investigational new drug, helps bladder pain when given as a rectal (inserted into the anus) foam. The study will test IW-3300. IW-3300 is a new drug that has been developed for treating people like you with interstitial cystitis/bladder pain syndrome. It is not yet approved by the United States Food and Drug Administration (FDA). It can only be used in a study like this one.
This study is closed
